Novel Cancer Screening (MCD Testing)

Closing the Cancer Screening Gap
While recommended screening tests exist for only five cancers (breast, colon, cervical, lung, and prostate), 70% of diagnosed cancers affect other areas.

Novel Cancer Screening tests such as Multi-cancer early detection (MCD) blood tests are an emerging approach to detecting more than 50 types of cancers early, when they are most treatable. Using MCD testing alongside existing screening tools is expected to improve early cancer detection for patients at an elevated risk of cancer.

Providence offers the GRAIL Galleri® test*, the only MCD test currently commercially available.  

*Please note: The Galleri MCD test is not covered by insurance and is billed directly to patients. Providence offers a special discounted rate available to enrolled providers.  

How the Galleri® MCD Test Works

The Galleri test can detect a cancer signal shared by more than 50 types of cancer through a routine blood draw¹. View the list of cancers detected by a shared cancer signal at Galleri.com/50-cancers.

1. Klein EA, et al. Clinical validation of a targeted methylation-based multi-cancer earlydetection test using an independent validation set.Ann Oncol. 2021;32(9):1167-1177. doi:10.1016/j.annonc.2021.05.806.
2. Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multi-cancer early detectionR): a prospective cohort study. Lancet. 2023;402:1251-1260. doi:10.1016/S0140- 36(23)01700-2.
GALLERI IS A REGISTERED TRADEMARK OF GRAIL, LLC.

Richard Clareman chose MCD testing for “peace of mind” because his family members carry a gene for cancer

"Novel Cancer Screenings like MCD tests fill a critical gap and Providence Genomics helps clinicians understand andoffer this test to patients who may benefit.It has helped me discover cancers in mypatients, and exclude cancer as anexplanation for clinical symptoms."

Ernie Prudente, MD, FACP

Internist, Westside InternalMedicine, Providence